Login to Your Account

Pharma: Other News To Note

Thursday, February 21, 2013
• UCB SA, of Atlanta, submitted regulatory filings in the U.S. and Europe to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adults with active psoriatic arthritis and for active axial spondyloarthritis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription